JBD upholds rigorous editorial policies to protect research integrity and ensure reliable diabetes bioinformatics scholarship. We follow international publishing standards for ethics, transparency, and peer review.

• Compliance with human and animal research ethics
• Disclosure of conflicts of interest and funding sources
• Data integrity and reproducibility expectations
• Plagiarism screening and originality checks

JBD uses single blind peer review. Reviewers evaluate methodology, data quality, and interpretability. Editors ensure feedback is constructive and aligned with journal scope.

• Corrections issued for factual or metadata errors
• Retractions for serious integrity concerns
• Editorial expressions of concern when needed
• Versioning for data or code updates

Authors should disclose AI assisted analysis or writing tools and describe how outputs were validated. Automated outputs must be checked for accuracy, bias, and reproducibility.

• Disclose any relationships with data providers or commercial partners.
• Report all funding sources and grant numbers accurately.
• State whether AI tools assisted analysis or writing and how outputs were verified.
• Ensure ethics approval numbers are included where relevant.
• Provide statements on patient consent for data reuse.
• Describe how conflicts of interest were managed within the author team.
• Report any deviations from registered protocols or study plans.
• Use plagiarism checks to confirm originality.
• Provide clear data availability and access statements.
• Include correction procedures for errors discovered after publication.
• Describe criteria for retractions or expressions of concern.
• Maintain transparency on peer review changes or appeals.
• Confirm that author contributions follow a standard taxonomy.
• State whether preprints were posted and link to them.
• Provide statements on image integrity and manipulation limits.
• Ensure clinical trial registration identifiers are reported.
• Document consent for use of patient images or identifiable data.
• Clarify how reviewer anonymity is protected in single blind review.
• Disclose any sponsorships or commercial partnerships tied to the study.
• Provide statements on data ownership and permission to publish.
• Report approvals for secondary use of clinical datasets.
• Ensure compliance with institutional review board requirements.
• Document any editorial corrections requested by authors.
• Provide transparency on peer review timelines when requested.
• Note whether registered reports or protocols were followed.
• Include statements about data retention and long term access.
• Confirm adherence to relevant reporting guidelines.
• Describe how anonymization was validated for shared data.
• State whether industry funding influenced study design.
• Provide contact information for ethics queries.
• Describe how authorship changes are handled after submission.
• State policies for duplicate submissions or redundant publication.
• Outline procedures for handling reviewer misconduct.
• Clarify procedures for handling suspected data fabrication.

JBD is committed to rigorous, transparent publishing in bioinformatics and diabetes research. We emphasize reproducible computational methods, clear data provenance, and ethical compliance across all article types.

The editorial office supports authors, editors, and reviewers with clear guidance and responsive communication. For questions about scope or workflow, contact [email protected].

We encourage continuous improvement in reporting practices and share updates that help the community maintain high standards in computational and translational diabetes research.